Intervention Review

You have free access to this content

Efficacy of psychostimulant drugs for amphetamine abuse or dependence

  1. Clara Pérez-Mañá1,*,
  2. Xavier Castells2,
  3. Marta Torrens3,
  4. Dolors Capellà4,
  5. Magi Farre1

Editorial Group: Cochrane Drugs and Alcohol Group

Published Online: 2 SEP 2013

Assessed as up-to-date: 1 AUG 2013

DOI: 10.1002/14651858.CD009695.pub2


How to Cite

Pérez-Mañá C, Castells X, Torrens M, Capellà D, Farre M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.: CD009695. DOI: 10.1002/14651858.CD009695.pub2.

Author Information

  1. 1

    Universitat Autònoma de Barcelona, Human Pharmacology and Clinical Neurosciences Research Group, Hospital del Mar Research Institute-IMIM, Parc de Salut Mar, and Department of Pharmacology, Therapeutics and Toxicology, Barcelona, Catalonia, Spain

  2. 2

    Universitat de Girona, Unit of Clinical Pharmacology, TransLab Research Group, Department of Medical Sciences, Girona, Catalonia, Spain

  3. 3

    Hospital del Mar Research Institute-IMIM, Parc de Salut Mar, Institute of Neuropsychiatry and Addiction, Disorders by Use of Substances Research Group, Barcelona, Spain

  4. 4

    Faculty of Medicine, Universitat de Girona, Unit of clinical pharmacology, Department of medical sciences, Girona, Catalonia, Spain

*Clara Pérez-Mañá, Human Pharmacology and Clinical Neurosciences Research Group, Hospital del Mar Research Institute-IMIM, Parc de Salut Mar, and Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Doctor Aiguader 88, Barcelona, Catalonia, 08003, Spain. cperez@imim.es.

Publication History

  1. Publication Status: New
  2. Published Online: 2 SEP 2013

SEARCH

[Figure 1]
Figure 1. Flow diagram for selection of studies.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 4]
Figure 4. Funnel plot of comparison: 1 Psychostimulants vs placebo for amphetamine dependence, outcome: 1.1 Amphetamine use (UA).
[Figure 5]
Figure 5. Funnel plot of comparison: 1 Psychostimulants vs placebo for amphetamine dependence, outcome: 1.3 Sustained abstinence.
[Figure 6]
Figure 6. Funnel plot of comparison: 1 Psychostimulants vs placebo for amphetamine dependence, outcome: 1.5 Retention in treatment.
[Figure 7]
Figure 7. Forest plot of comparison: 8 Post hoc analysis, outcome: 8.1 Amphetamine use (UA).
[Analysis 1.1]
Analysis 1.1. Comparison 1 Psychostimulants vs placebo for amphetamine dependence, Outcome 1 Amphetamine use (UA).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Psychostimulants vs placebo for amphetamine dependence, Outcome 2 Amphetamine use (hair analysis).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Psychostimulants vs placebo for amphetamine dependence, Outcome 3 Sustained abstinence.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Psychostimulants vs placebo for amphetamine dependence, Outcome 4 Self-reported amphetamine use.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Psychostimulants vs placebo for amphetamine dependence, Outcome 5 Retention in treatment.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Psychostimulants vs placebo for amphetamine dependence, Outcome 6 Amphetamine craving.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Psychostimulants vs placebo for amphetamine dependence, Outcome 7 Dropouts due to any adverse event.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Psychostimulants vs placebo for amphetamine dependence, Outcome 8 Dropouts due to cardiovascular adverse events.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Psychostimulants vs placebo for amphetamine dependence, Outcome 9 Dropouts due to psychiatric adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Subgroup analysis: type of drug, Outcome 1 Amphetamine use (UA).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Subgroup analysis: type of drug, Outcome 2 Amphetamine use (hair analysis).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Subgroup analysis: type of drug, Outcome 3 Sustained abstinence.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Subgroup analysis: type of drug, Outcome 4 Self-reported amphetamine use.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Subgroup analysis: type of drug, Outcome 5 Retention in treatment.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Subgroup analysis: type of drug, Outcome 6 Amphetamine craving.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Subgroup analysis: type of drug, Outcome 7 Dropouts due to any adverse event.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Subgroup analysis: type of drug, Outcome 8 Dropouts due to cardiovascular adverse events.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Subgroup analysis: type of drug, Outcome 9 Dropouts due to psychiatric adverse events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Subgroup analysis: type of dependence, Outcome 1 Amphetamine use (UA).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Subgroup analysis: type of dependence, Outcome 2 Amphetamine use (hair analysis).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Subgroup analysis: type of dependence, Outcome 3 Sustained abstinence.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Subgroup analysis: type of dependence, Outcome 4 Self-reported amphetamine use.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Subgroup analysis: type of dependence, Outcome 5 Retention in treatment.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Subgroup analysis: type of dependence, Outcome 6 Amphetamine craving.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Subgroup analysis: type of dependence, Outcome 7 Dropouts due to any adverse event.
[Analysis 3.8]
Analysis 3.8. Comparison 3 Subgroup analysis: type of dependence, Outcome 8 Dropouts due to cardiovascular adverse events.
[Analysis 3.9]
Analysis 3.9. Comparison 3 Subgroup analysis: type of dependence, Outcome 9 Dropouts due to psychiatric adverse events.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Subgroup analysis: comorbid ADHD as inclusion criterion, Outcome 1 Amphetamine use (UA).
[Analysis 4.2]
Analysis 4.2. Comparison 4 Subgroup analysis: comorbid ADHD as inclusion criterion, Outcome 2 Amphetamine use (hair analysis).
[Analysis 4.3]
Analysis 4.3. Comparison 4 Subgroup analysis: comorbid ADHD as inclusion criterion, Outcome 3 Sustained abstinence.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Subgroup analysis: comorbid ADHD as inclusion criterion, Outcome 4 Self reported amphetamine use.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Subgroup analysis: comorbid ADHD as inclusion criterion, Outcome 5 Retention in treatment.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Subgroup analysis: comorbid ADHD as inclusion criterion, Outcome 6 Amphetamine craving.
[Analysis 4.7]
Analysis 4.7. Comparison 4 Subgroup analysis: comorbid ADHD as inclusion criterion, Outcome 7 Dropouts due to any adverse event.
[Analysis 4.8]
Analysis 4.8. Comparison 4 Subgroup analysis: comorbid ADHD as inclusion criterion, Outcome 8 Dropouts due to cardiovascular adverse events.
[Analysis 4.9]
Analysis 4.9. Comparison 4 Subgroup analysis: comorbid ADHD as inclusion criterion, Outcome 9 Dropouts due to psychiatric adverse events.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Subgroup analysis: data publication, Outcome 1 Amphetamine use (UA).
[Analysis 5.2]
Analysis 5.2. Comparison 5 Subgroup analysis: data publication, Outcome 2 Amphetamine use (hair analysis).
[Analysis 5.3]
Analysis 5.3. Comparison 5 Subgroup analysis: data publication, Outcome 3 Sustained abstinence.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Subgroup analysis: data publication, Outcome 4 Self reported amphetamine use.
[Analysis 5.5]
Analysis 5.5. Comparison 5 Subgroup analysis: data publication, Outcome 5 Retention in treatment.
[Analysis 5.6]
Analysis 5.6. Comparison 5 Subgroup analysis: data publication, Outcome 6 Amphetamine craving (at the end of study).
[Analysis 5.7]
Analysis 5.7. Comparison 5 Subgroup analysis: data publication, Outcome 7 Dropouts due to any adverse event.
[Analysis 5.8]
Analysis 5.8. Comparison 5 Subgroup analysis: data publication, Outcome 8 Dropouts due to cardiovascular adverse events.
[Analysis 5.9]
Analysis 5.9. Comparison 5 Subgroup analysis: data publication, Outcome 9 Dropouts due to psychiatric adverse events.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Subgroup analysis: clinical trial reporting quality (incomplete outcome data), Outcome 1 Amphetamine use (UA).
[Analysis 6.2]
Analysis 6.2. Comparison 6 Subgroup analysis: clinical trial reporting quality (incomplete outcome data), Outcome 2 Amphetamine use (hair analysis).
[Analysis 6.3]
Analysis 6.3. Comparison 6 Subgroup analysis: clinical trial reporting quality (incomplete outcome data), Outcome 3 Sustained abstinence.
[Analysis 6.4]
Analysis 6.4. Comparison 6 Subgroup analysis: clinical trial reporting quality (incomplete outcome data), Outcome 4 Self reported amphetamine use.
[Analysis 6.5]
Analysis 6.5. Comparison 6 Subgroup analysis: clinical trial reporting quality (incomplete outcome data), Outcome 5 Retention in treatment.
[Analysis 6.6]
Analysis 6.6. Comparison 6 Subgroup analysis: clinical trial reporting quality (incomplete outcome data), Outcome 6 Amphetamine craving.
[Analysis 6.7]
Analysis 6.7. Comparison 6 Subgroup analysis: clinical trial reporting quality (incomplete outcome data), Outcome 7 Dropouts due to any adverse event.
[Analysis 6.8]
Analysis 6.8. Comparison 6 Subgroup analysis: clinical trial reporting quality (incomplete outcome data), Outcome 8 Dropouts due to cardiovascular adverse events.
[Analysis 6.9]
Analysis 6.9. Comparison 6 Subgroup analysis: clinical trial reporting quality (incomplete outcome data), Outcome 9 Dropouts due to psychiatric adverse events.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Sensitivity analysis of the safety measures, Outcome 1 Dropouts due to any adverse event.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Sensitivity analysis of the safety measures, Outcome 2 Dropouts due to cardiovascular adverse events.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Sensitivity analysis of the safety measures, Outcome 3 Dropouts due to psychiatric adverse events.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Post hoc analysis, Outcome 1 Amphetamine use (UA).
[Analysis 8.2]
Analysis 8.2. Comparison 8 Post hoc analysis, Outcome 2 Amphetamine use (hair analysis).
[Analysis 8.3]
Analysis 8.3. Comparison 8 Post hoc analysis, Outcome 3 Sustained abstinence.
[Analysis 8.4]
Analysis 8.4. Comparison 8 Post hoc analysis, Outcome 4 Self reported amphetamine use.
[Analysis 8.5]
Analysis 8.5. Comparison 8 Post hoc analysis, Outcome 5 Retention in treatment.
[Analysis 8.6]
Analysis 8.6. Comparison 8 Post hoc analysis, Outcome 6 Amphetamine craving.
[Analysis 8.7]
Analysis 8.7. Comparison 8 Post hoc analysis, Outcome 7 Dropouts due to any adverse event.
[Analysis 8.8]
Analysis 8.8. Comparison 8 Post hoc analysis, Outcome 8 Dropouts due to cardiovascular adverse events.
[Analysis 8.9]
Analysis 8.9. Comparison 8 Post hoc analysis, Outcome 9 Dropouts due to psychiatric adverse events.